InvestorsHub Logo
Followers 74
Posts 10289
Boards Moderated 1
Alias Born 11/22/2004

Re: None

Thursday, 06/26/2014 10:25:47 AM

Thursday, June 26, 2014 10:25:47 AM

Post# of 10476
ONVO news: "Organovo Reports Positive Results from a Collaborative Study Using Organovo's 3D Human Liver Tissues -8-K
8:15a ET June 26, 2014 (Benzinga) Print

On June 26, 2014, Organovo Holdings (NASDAQ: ONVO) announced that a key opinion leader reported positive results from a collaborative study conducted with Organovo scientists using Organovo's 3D Human Liver Tissues. Dr. Adrian Roth, Head of Mechanistic Safety for Roche Pharmaceutical Research and Early Development at the Roche Innovation Center Basel, presented results from a collaborative study executed by Organovo scientists at the Company's San Diego facility. The results of the study showed Organovo's 3D Liver system was able to distinguish a toxic drug known to cause drug induced liver injury (DILI) from a close chemical analogue that is known to be non-toxic. Further, the toxicity of the toxic compound was detected at physiologically relevant doses, an important observation not previously reported with the same compounds in other model liver systems. Dr. Roth presented the material at the "3D Cell Culture 2014" conference in Freiburg, Germany on June 25, 2014.

Organovo continues to be on track to launch its upcoming 3D Human Liver Tissue on its previously announced timelines, before the end of 2014. Organovo announced in April that it had initiated contracting for toxicity testing using its 3D Human Liver Tissue for selected clients prior to full release, making 3D Human Liver Tissue technology available to clients who have specific testing needs in their preclinical drug discovery programs. Organovo began signing research service contracts at that time and is in discussions with additional customers for near-term needs, in a limited initial release of this service. Customers with needs in a research setting that align with the preliminary offering are now able to engage, with fuller testing services including metabolic function to be offered over time. All testing will be performed at Organovo's facility by Organovo's laboratory services tissue experts".

© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Rayank

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ONVO News